secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001104659-25-028015
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap reports positive sirexatamab CRC data: 32% higher ORR, 3.5mo PFS in high DKK1 patients
--------------------------------------------------------------------------------

- High DKK1 patients: sirexatamab arm ORR 48% vs 15.8% control; median PFS 9.36 vs 5.88 mo (HR 0.46); OS HR 0.09.
- No prior anti-VEGF patients: ORR 55.1% vs 32.6%; median PFS 10.94 vs 8.34 mo (HR 0.59); OS immature.
- FY2024 net loss $67.6M ($81.4M in 2023); R&D expenses $57.2M ($73.2M in 2023).
- Cash and equivalents $47.2M at Dec 31, 2024; engaged financial advisor for business development.
- FL-501 abstract accepted at AACR 2025; preclinical data to be presented April 25-30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465925028015/0001104659-25-028015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465925028015/tm2510101d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-028015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer